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Cellular senescence acts as a potent barrier to tumorigenesis and contributes to the anti-tumor activity of
certain chemotherapeutic agents. Senescent cells undergo a stable cell cycle arrest controlled by RB and p53
and, in addition, display a senescence-associated secretory phenotype (SASP) involving the production of
factors that reinforce the senescence arrest, alter the microenvironment, and trigger immune surveillance of
the senescent cells. Through a proteomics analysis of senescent chromatin, we identified the nuclear factor-kB
(NF-kB) subunit p65 as a major transcription factor that accumulates on chromatin of senescent cells. We found
that NF-kB acts as a master regulator of the SASP, influencing the expression of more genes than RB and p53
combined. In cultured fibroblasts, NF-kB suppression causes escape from immune recognition by natural killer
(NK) cells and cooperates with p53 inactivation to bypass senescence. In a mouse lymphoma model, NF-kB
inhibition bypasses treatment-induced senescence, producing drug resistance, early relapse, and reduced
survival. Our results demonstrate that NF-kB controls both cell-autonomous and non-cell-autonomous aspects
of the senescence program and identify a tumor-suppressive function of NF-kB that contributes to the outcome
of cancer therapy.
[Keywords: NF-kB; SASP; senescence; lymphoma; chemoresistance]
Supplemental material is available for this article.
Received June 22, 2011; revised version accepted September 1, 2011.
Cellular senescence is an anti-proliferative program that
limits the propagation of damaged cells at risk of neo-
plastic transformation (Campisi and d’Adda di Fagagna
2007). Identified initially as the process that limits the
replicative life span of cultured human cells, senescence
also can be triggered acutely in cells by activated onco-
genes, leading to ‘‘oncogene-induced senescence’’ that
may halt the progression of premalignant lesions (Mooi
and Peeper 2006). Furthermore, senescence can be acti-
vated by various forms of DNA damage, including that
produced by cytotoxic chemotherapeutic agents (Schmitt
et al. 2002; te Poele et al. 2002; Roninson 2003). Thus, in
addition to acting as a potent barrier to tumorigenesis,
senescence contributes to the cytotoxicity of certain anti-
cancer agents, thus dictating the treatment outcome of
chemotherapy (Kuilman et al. 2010).
Cells undergoing senescence have characteristic fea-
tures, displaying a large and flat morphology, an increase
in senescence-associated b-galactosidase (SA-b-gal) activity,
and, in some cell types, a discernible change in chromatin
organization known as senescence-associated heterochro-
matin foci (SAHF) (Kuilman et al. 2010). Molecularly,
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senescent cells undergo a stable cell cycle arrest executed
by interplay between the RB and p53 tumor suppressor
pathways (Serrano et al. 1997; Zhu et al. 1998) and,
accordingly, often accumulate the p16INK4a, p15INK4b,
and p21Cip1/Waf1 cyclin-dependent kinase inhibitors that
engage the RB pathway or mediate p53 effects (Lin and
Benchimol 1997; Woods et al. 1997; Malumbres et al.
2000). Together, these changes generate a repressive chro-
matin environment that leads to the stable repression of
E2F-responsive genes (Narita et al. 2003).
In addition to executing a cell cycle arrest program,
senescent cells undergo massive changes in the expression
of genes that are predicted to influence the tissue micro-
environment in vivo (Campisi and d’Adda di Fagagna 2007).
Thus, in addition to the repression of proliferation genes,
senescent cells often down-regulate extracellular matrix
proteins and up-regulate extracellular matrix-degrading
enzymes (Shelton et al. 1999). They also secrete a variety of
inflammatory cytokines and other immune modulators
(Freund et al. 2010). Collectively, these changes have been
referred to as the senescence-associated secretory pheno-
type (SASP) or senescence messaging secretome (SMS)
(Coppe et al. 2008; Kuilman and Peeper 2009).
Although components of the SASP were initially stud-
ied primarily as markers of senescence (Kortlever et al.
2006), it is now clear that SASP components actively
participate in the senescence process. For example, key
SASP factors, including interleukin-6 (IL-6) and IL-8, act
in an autocrine feedback loop to reinforce the senescence
growth arrest (Kortlever et al. 2006; Acosta et al. 2008;
Kuilman et al. 2008). In addition, secreted factors from
senescent cells may act in a paracrine manner to trigger
senescence or, conversely, stimulate proliferation and/or
transformation of adjacent immortalized cells (Krtolica
et al. 2001; Wajapeyee et al. 2008). Finally, IL-6, IL-8, and
other secreted factors attract immune cells that, together
with the increased expression of immune cell-interacting
molecules on senescent cells, can lead to immune
surveillance and subsequent elimination of senescent
cells. Depending on the biological context, this process
can facilitate tumor regression or the resolution of wound
healing responses (Xue et al. 2007; Krizhanovsky et al.
2008). Despite the potential importance of the SASP
to the biology of senescence, little is known about how
the process is regulated, and its impact on cancer pheno-
types has not been directly assessed.
We and others have previously shown that senescent
cells undergomassive changes in gene expression that are
associatedwith chromatinmodifications that, in some cell
types, lead to marked changes in the binding of transcrip-
tion factors and other chromatin modifiers, including RB,
p53, and the high-mobility group A proteins (HMGA1 and
HMGA2) (Narita et al. 2003, 2006; Zhang et al. 2007). Here
we perform a nonbiased analysis of proteins bound to
chromatin in senescent cells and identify the nuclear
factor-kB (NF-kB) p65 subunit as one of the most signifi-
cantly enriched transcriptional modifiers that bind senes-
cent cell chromatin. We find that NF-kB is a master
regulator of the SASP and then use this to further probe
the impact of SASP biology on the senescence program.
Results
Identification and activation of NF-kB in senescent cells
To identify novel factors that contribute to the regulation
of cellular senescence, we performed global proteomics
analyses of chromatin compositions of both growing and
oncogenic H-RasV12-induced senescent IMR-90 fibro-
blasts, a well-characterized system of cellular senescence
(Campisi 2005). From two independent sample sets, we
identified 2362 proteins that were reproducibly enriched
in the chromatin fraction of senescent IMR-90 cells,
including senescence benchmark proteins HMGA1 and
HMGA2 (Supplemental Material; Supplemental Table 1)
(Narita et al. 2006). Other known senescence regulators
we identified as more tightly associated with senescent
chromatin include the promyelocytic leukemia protein
(PML) and CCAAT/enhancer-binding protein b (C/EBPb)
(Ferbeyre et al. 2000; Pearson et al. 2000; Kuilman et al.
2008). We did not detect the presence of p53 or RB in
either growing or senescent chromatin, suggesting these
factors fell below the limit of detection of this method
(data not shown).
We chose to initially focus on transcription factors
whose up-regulation might coordinate gene expression
changes that drive senescence. Among the 18 transcription
factors we identified, the p65 subunit of NF-kB stood out
for its strong accumulation on senescent chromatin and
its link to genes known to contribute to senescence and
the SASP (Fig. 1A). Interestingly, the vast majority of
work onNF-kB has demonstrated pro-oncogenic functions,
although a role for NF-kB in anti-proliferative responses
has been documented in some contexts as well (Basseres
and Baldwin 2006). Nonetheless, the potential contribu-
tion ofNF-kB to senescence remains controversial, as some
studies suggest a role in regulation of SASP targets, while
others indicate that enforced NF-kB expression can bypass
senescence (Acosta et al. 2008; Batsi et al. 2009; Wang
et al. 2009; Rovillain et al. 2011). Given the striking
accumulation of p65 in chromatin during senescence,
we decided to explore its action in a systematic way.
NF-kB complexes involve dimerization of five mem-
bers—p65 (RelA), RelB, c-Rel, p50/p105 (NF-kB1), and
p52/p100 (NF-kB2)—the most common form being a di-
mer composed of p50 and p65 subunits (Hoffmann and
Baltimore 2006). NF-kB is kept inactive through its
sequestration in the cytoplasm by the inhibitor of kB (IkB)
family of proteins. Upon signals elicited by bacterial
products, cytokines, viral expression, growth factors, and
stress stimuli, kinases catalyze the phosphorylation of IkB
and the p65 subunit, triggering p65 release and the trans-
location of p65/p50 transcription factors into the nucleus,
where they activate a range of genes involved in immune
and inflammatory responses (Wan and Lenardo 2009).
Consistent with the proteomics results, immunoblot-
ting confirmed that p65 accumulated on chromatin in
senescent cells (Fig. 1B). Moreover, immunoblotting with
phospho-specific antibodies indicated that p65 was phos-
phorylated on Ser 536, and immunofluorescence showed
that p65 accumulated in the nucleus of SAHF-positive
Chien et al.
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cells during senescence, suggesting p65 activation (Fig.
1C,D). Importantly, nuclear translocation and accumula-
tion of p65 occurred in senescent IMR-90 cells triggered
to senesce by either oncogenic H-RasV12 or the chemo-
therapeutic drug etoposide, suggesting that activation of
NF-kB in senescent cells is independent of the specific
senescence trigger used (Fig. 1D,E).
We also examined the kinetics of NF-kB activation
during senescence by expressing a 4-hydroxy-tamoxifen
(4-OHT)-inducible estrogen receptor (ER) module fused to
H-RasV12 (H-RasV12-ER). IMR-90 cells became senescent
after 6 d of induction of H-RasV12 by 4-OHT, as indicated
by the formation of SAHF and accumulation of p16INK4a
(Fig. 1F,G). Notably, NF-kB activation, as assessed by p65
nuclear accumulation and phosphorylation, was clearly
detectable after 6 d of induction of H-RasV12, which
coincided with cell cycle exit and SAHF formation (Fig.
1F,G; Narita et al. 2003). Therefore, in this setting, NF-kB
activation is likely an indirect consequence of Ras sig-
naling and coincides with the onset of senescence.
NF-kB controls the SASP
To address the function of NF-kB during senescence, we
examined the consequences of suppressing p65 function
on senescence phenotypes using RNAi. We designed
several miR30-based shRNAs against p65, and two effi-
ciently knocked down p65 protein levels in IMR-90 cells
(Fig. 2A). In IMR-90 cells, this level of p65 knockdown
was not sufficient to bypass senescence (see Fig.3). Such
a result is not particularly surprising, as knockdown of no
single senescence regulator has been shown to bypass the
arrest program in IMR-90 fibroblasts (Serrano et al. 1997;
Campisi 2005; Narita et al. 2006). This situation enabled
us to identify potential targets of NF-kB during senes-
cence while avoiding any potentially confounding varia-
tion in proliferative states between cells triggered to
senesce in the presence or absence of functional NF-kB.
Transcriptional profiling was performed on growing or
H-RasV12-induced senescent IMR-90 cells expressing
shRNAs targeting p65, p53, or the nonexpressed protein
firefly luciferase (Luc) as a control. RNA from two in-
dependent experiments was hybridized to the Affymetrix
Human Genome U133 Plus 2.0 microarrays. Data were
also compared with a published data set that identified
RB-regulated genes in senescence (Chicas et al. 2010). We
identified 406 genes that were consistently differentially
expressed (greater than twofold change) upon p65 loss in
senescent cells, whereas in growing cells, only 24 genes
were similarly affected. In addition, while 289 genes failed
to be induced upon suppression of p65 in senescent cells,
suppression of p53 and RB down-regulated only 85 and 215
Figure 1. NF-kB is activated in senescent cells. (A)
A scatter plot of 18 transcription factors identified
from mass spectrometry (refer to Supplemental
Table 1 for the full list of proteins identified). The
line represents values of y = x, which means the
expression is the same for growing and senescent
cells. (B) Increased binding of p65 to senescent
chromatin fraction. Chromatin fractions were
isolated from growing (containing empty vector,
abbreviated as V) and senescent IMR-90 cells
induced by H-RasV12 and analyzed by Western
blotting using the indicated antibodies. H3 was
used as loading control. (C) Hyperphosphorylation
of p65 on Ser 536 in senescent cells. Whole-cell
lysates from growing and H-RasV12-induced sen-
escent IMR-90 cells were analyzed by Western
blotting using the indicated antibodies. Accumu-
lation of p53, p16INK4a, and p15INK4b proteins are
shown as senescence markers. Total p65 was used
as loading control. (D) Senescent cells show nu-
clear translocation and accumulation of p65.
Growing and senescent IMR-90 cells induced
by either H-RasV12 or etoposide (100 mM) were
immunostained with anti-p65 antibodies (top
panels) and counterstained with DAPI (bottom
panels) to show SAHF formation. (E) Whole-cell
lysates from growing and etoposide-induced sen-
escent IMR-90 cells were analyzed by Western
blotting using the indicated antibodies. (F) Nu-
clear translocation of p65 coincides with senes-
cence. IMR-90 cells containing RasV12-ER were
treated with 4-OHT (200 mM) for the indicated
time. Cells were immunostained with anti-p65
antibodies (top panels) and counterstained with DAPI (bottom panels). (G) Whole-cell lysates from cells in parallel with
conditions described in F were collected and analyzed by Western blotting using the indicated antibodies.
A tumor-suppressive function of NF-kB
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genes, respectively. Unsupervised hierarchical clustering
of the arrays using the sets of differentially expressed genes
segregated the samples into two large classes: without
H-RasV12 (growing) and with H-RasV12 (senescent) (Fig. 2B).
Although cells expressing RB shRNAs were the most
distant clusters in growing cells, additional clustering
of the genes within the senescent group clearly segregated
cells expressing p65 shRNAs from those expressing con-
trol (Luc), p53, or RB shRNAs. Indeed, a more detailed
analysis of E2F target genes, which are negatively regu-
lated by RB (Chen et al. 2009), indicates that NF-kB has
little impact on their expression (Supplemental Fig. 1),
consistent with each factor controlling parallel pathways.
To broadly characterize the cellular processes altered
upon disruption of NF-kB in senescent cells, we tested for
enrichment of gene ontology (GO) terms. Unbiased GO
analysis of these down-regulated genes showed a signifi-
cant enrichment (P < 0.05 with Benjamini correction) for
a total of 47 GO terms, including ‘‘positive regulation of
NF-kB activity’’ (Fig. 2C). One of the significant GO terms
was ‘‘immune response,’’ which comprised 17 genes,
including IL-6, IL-8, CXCL1, and ICAM1 (Fig. 2D). Im-
portantly, these genes were shown by RT-qPCR to be
affected by NF-kB inhibition in cells expressing p65
shRNAs or treated with the NF-kB inhibitor BAY 11-7082
(Fig. 2E,F). Other known SASP components, including
several matrix metalloproteinases and noninflammatory
response genes, also failed to be induced in p65 shRNA-
expressing cells triggered to senesce (Supplemental Table
2). Therefore, while NF-kB suppression has a limited
impact on gene expression in normal growing cells, it has
a major impact on global gene expression in senescent
cells, controlling a transcriptional module that is larger
and distinct from those controlled by the established
senescence regulators p53 and RB.
The fact that the expression of many immune modu-
latory genes and secreted factors depends on NF-kB
expression raises the possibility that it promotes immune
surveillance of senescent cells—a non-cell-autonomous
component of the senescence program. Indeed, senescent
Figure 2. NF-kB mediates the SASP. (A) IMR-90
cells were infected with the indicated shRNAs with
or without H-RasV12. shRNA against firefly lucifer-
ase (Luc.) was used as a control. Whole-cell lysates
were collected 8 d following the completion of
selection and analyzed by Western blotting using
the indicated antibodies. Total ERK was used as
loading control. (B) Hierarchical clustering analysis
of differentially expressed genes from IMR-90 cells
expressing each indicated shRNA with and without
H-RasV12. The shRNA against p65 that showed the
best knockdown efficiency by Western blotting
(shp65-1) was used. (C) GO analysis of significantly
down-regulated genes upon loss of p65 function (P <
0.05). Differentially expressed genes were identified
by comparing samples with shRNA against p65
with that of luciferase in H-RasV12-induced senes-
cent IMR-90 cells. (D) Heat map of genes comprising
the GO term ‘‘immune response.’’ Loss of p65
significantly down-regulated immune response
genes (P = 3.7 3 102 with Benjamini correction).
(E) Suppression of p65 function abrogates the in-
duction of IL-6, IL-8, CXCL1, and ICAM-1 in sen-
escent cells. Total RNA was extracted and analyzed
by RT-qPCR with primer sets against the indicated
transcripts. Expression is normalized to the expres-
sion of b-actin and is expressed as the fold change
relative to growing IMR-90 cells. Values are means +
SEM of two independent samples with triplicate
qPCR. (Vec.) Vector; (R.) H-RasV12; (Luc.) shRNA
against luciferase; (p65-1 and p65-2) two shRNAs
against p65. (F) NF-kB inhibitor BAY11-7082 (BAY)
also prevents the induction of IL-6, IL-8, CXCL1,
and ICAM-1 in senescent cells. IMR-90 cells were
infected with the indicated shRNAs with or without
H-RasV12. Eight days following the completion of selection, senescent IMR-90 cells were treated with 10 mM BAY11-7082 for 2 d before
harvesting. Expression is normalized to the expression of b-actin and is expressed as the fold change relative to growing cells
(containing vector). Values are means + SEM of two independent samples with triplicate qPCRs. (G) NF-kB is required for recognition
and killing by NK cells. IMR-90 cells expressing the indicated vectors were cocultured with YT cells (a human NK cell line) for 12 h.
Attached viable senescent cells were stained with crystal violet. Crystal violet quantification at OD 595 was performed and the
percentage cytotoxicity was calculated as crystal violet absorbance in the presence of YTcells relative to senescent cells cultured in the
absence of YT cells. Values represent means + SEM of three independent experiments; (*) P < 0.05 using Student’s t-test.
Chien et al.
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IMR-90 cells become hypersensitive to targeting by
natural killer (NK) cells as assessed by short-term cyto-
toxicity assays in vitro (Krizhanovsky et al. 2008), an
effect that was strongly impaired by suppression of p65
(Fig. 2G). Together, our results indicate that NF-kB
controls a discrete transcriptional module that influences
non-cell-autonomous aspects of the senescence program.
NF-kB cooperates with p53 to promote senescence
Our transcriptional profiling data suggest that NF-kB
controls a distinct transcriptional module compared with
that regulated by p53. To test whether these regulators
cooperate during senescence, we developed a polycistronic
shRNA construct (Chicas et al. 2010) capable of cosup-
pressing p53 and p65 (Fig. 3A). Similar levels of p53 and
p65 knockdown were achieved with the ‘‘tandem’’ hairpin
in senescent IMR-90 cells, demonstrating that the effi-
ciency of the tandem construct was equivalent to that of
the individual hairpins (Fig. 3B). While inhibiting p53 or
p65 expression alone had no overt effect on the growth
arrest phenotype induced by oncogenic H-RasV12 in IMR-
90 cells, inhibiting both p53 and p65 simultaneously
promoted cell growth as measured by reduced accumu-
lation of p16INK4a protein (Fig. 3B), an increase in cyclin
A protein (Supplemental Fig. 2), increased 5-bromo-29-
deoxyuridine (BrdU) incorporation (Fig. 3C), and an
increased ability of cells to form colonies when seeded
at limiting dilution (Fig. 3D). Consistent with this
observation, cells cosuppressing p53 and p65 failed to
induce SA-b-gal (Fig. 3E). Comparable results were observed
using either oncogenicH-RasV12 or etoposide as a senescence
stimulus (Fig. 3E).
These above results suggest that themolecular programs
regulated byNF-kB are complementary to those controlled
by p53. Nonetheless, such interactions may be cell type-
specific, as p65 shRNAs were sufficient to bypass
H-RasV12-induced senescence in human BJ fibroblasts upon
loss of p65 function (Fig. 3F,G), perhaps owing to the less
robust senescence program in this cell type (Beausejour
et al. 2003). Accordingly, suppression of the NF-kB target
IL-6 can impair senescence in human diploid fibroblasts
containing shRNAs against p16INK4a (Kuilman et al. 2008).
These results imply that in addition to influencing the
Figure 3. NF-kB cooperates with p53 to promote
senescence. (A) A schematic diagram of the poly-
cistronic shRNA construct used to simultaneously
knock down p65 and p53. (Tan) Tandem hairpin.
The shRNA against p65 that showed the best
knockdown efficiency by Western blotting (shp65-
1) was used. (B) Coinhibition of p53 and p65 expres-
sion. IMR-90 cells were infected with the indicated
shRNAs and H-RasV12. Whole-cell lysates were
collected 8 d post-selection and analyzed by Western
blotting using the indicated antibodies. Tubulin is
shown as a loading control. (C) Coinhibition of p53
and p65 bypasses senescence. IMR-90 cells infected
with the indicated shRNAs with or without
H-RasV12 were analyzed for BrdU incorporation 8
d post-selection. Values represent means + SEM of
two independent experiments; (*) P < 0.005 using
Student’s t-test. (D) IMR-90 cells infected with the
indicated shRNAs and H-RasV12 were plated at
increasing cell density 8 d post-selection. Cells were
cultured for an additional 2 wk, stained with crystal
violet, and analyzed for colony formation. (E) IMR-
90 cells were infected with the indicated shRNAs
and triggered to undergo senescence by either
H-RasV12 or 100 mM etoposide. Eight days post-
selection, cells were assayed for SA-b-gal activity.
Values represent means + SEM of three independent
experiments; (*) P < 0.05 using Student’s t-test. (F) BJ
cells were infected with the indicated shRNAs
together with H-RasV12 to trigger senescence. Cells
were assayed for SA-b-gal activity 8 d post-selection.
Values represent means + SEM of three independent
experiments; (*) P < 0.05 using Student’s t-test. (G)
BJ cells were infected with the indicated shRNAs
with or without H-RasV12. Cells were assayed for
BrdU incorporation 8 d post-selection. Values repre-
sent means + SEM of three independent experi-
ments; (*) P < 0.05 using Student’s t-test.
A tumor-suppressive function of NF-kB
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non-cell-autonomous aspects of the senescence program,
NF-kB can contribute to the cell cycle arrest as well.
Modulation of NF-kB activity in lymphomas
using tetracycline-regulatable p65 shRNA
In addition to its role in preventing tumorigenesis, cellular
senescence can contribute to the anti-cancer activity of
certain chemotherapeutic drugs, particularly in circum-
stances in which apoptosis is suppressed (Roninson 2003).
For example, Em-myc lymphomas expressing the anti-
apoptotic protein Bcl-2 undergo senescence in response
to cytotoxic chemotherapy, which contributes to enhanced
survival in mice compared with animals harboring lym-
phomas with defective senescence machinery (Schmitt
et al. 2002). To examine the contribution of NF-kB to
cellular senescence in vivo, we developed two novel
platforms that enabled us to conditionally regulate endog-
enous NF-kB activity in murine lymphomas in vivo. One
system involved the production of transgenic mice harbor-
ing tetracycline-responsive p65 shRNA targeted to the
ColA1 locus by recombination-mediated cassette ex-
change in embryonic stem (ES) cells, which provided
a highly efficient system for producing mice in which
endogenous gene expression can be controlled in a con-
stitutive or tissue-restrictive manner in transgenic mice
(Premsrirut et al. 2011). The other system involved amore
flexible variation of the Em-myc model produced by
retrovirally cotransducing c-Myc and Bcl-2 directly into
pre-B cells rather than expressing each from a tissue-
specific transgene. We envisioned that combination of
these systems would enable the rapid production of
leukemias/lymphomas in which endogenous NF-kB ex-
pression could be controlled in vivo, avoiding extensive
intercrossing of genetically engineered strains.
Bonemarrowwas isolated from transgenicmice carrying
the Rosa reverse tetracycline-controlled transcriptional
activator (Rosa-rtTA) and a tetracycline-responsive p65
miR30 design shRNA (TRE-shRNA) linked to green fluo-
rescence protein (GFP). Cells were retrovirally transduced
with a construct coexpressing both Bcl-2 and c-Myc (Fig.
4A) and maintained in culture conditions known to sup-
port pre-B-cell growth (Whitlock and Witte 1987). Impor-
tantly, these cells achieved substantial p65 knockdown
after 6 d of doxycycline (Dox) treatment in culture (Fig. 4B).
Following transplantation of these cells into multiple
nontransgenic, sublethally irradiated recipient mice (BL6/
Ly5.1), recipient animals developed palpable prescapular
and cervical lymph nodes and a marked lymphocytosis
and splenomegaly within 3 wk (data not shown). Each
animal displayed pathology consistent with an acute
lymphoblastic leukemia/lymphoma leading to lymph node
effacement (Fig. 4C), involvement of splenic white and red
pulp (Fig. 4D), and infiltration in perivascular areas of the
liver (Fig. 4E).
A notable feature of the lymph node histopathology
was a low number of tingible body macrophages, suggest-
ing the presence of few apoptotic cells (data not shown).
Accordingly, the lymphoma cells were refractory to
killing by adriamycin (ADR), a chemotherapeutic agent
commonly used to treat human B-cell malignancies, and
failed to induce the apoptotic effector cleaved caspase-3
at the time points examined (Fig. 4F). As expected,
however, these cells remained sensitive to the Bcl-2
antagonist ABT-737 (Mason et al. 2008). In vivo, treat-
ment with cyclophosphamide (CTX) also did not trigger
substantial apoptosis (data not shown) or release of the
necrotic marker high-mobility group box 1 (HMGB1)
protein (Fig. 4G; Scaffidi et al. 2002; Zong et al. 2004).
However, as previously described, CTX treatment resulted
in the induction of senescence as measured by accumu-
lation of the senescence marker p15INK4b (Fig. 5A) and
SA-b-gal staining (Fig. 5B). Therefore, these B-cell malig-
nancies provide a suitable context to interrogate therapy-
induced senescence using inducible shRNAs.
Figure 4. Generation of Myc-Bcl-2-driven lymphomas with
a tetracycline-regulatable p65 shRNA. (A) Bone marrow from
4- to 5-wk-old female mice carrying the Rosa-rtTA and the TRE-
shRNAwere infected with a vector coexpressing Myc and Bcl-2.
Cells were explanted into pre-B-cell culture medium containing
IL-7 for 1 wk. (B) Efficient knockdown of p65 after 6 d of Dox
treatment. Cells from A were treated with or without Dox (1 mg/
mL) for the indicated time, and whole-cell lysates were collected
and analyzed by Western blotting using the indicated antibodies.
Sorted B220+ cells from wild-type animals were used as a control.
(C–E) Lymphoblastic neoplasms in recipient animals. Hematoxylin
and eosin staining of lymph node (C), spleen (D), and liver (E)
shows lymphoblastic disease. (W) Splenic white pulp; (R) splenic
red pulp; lymphoma infiltrates both. (F) Myc- and Bcl-2-driven pre-
B cells are resistant to apoptosis induced by chemotherapeutic
agents. Cells from A were left untreated or treated with either
ADR (250 ng/mL) or ABT-737 (10 mM) for 24 h in vitro. Whole-cell
lysates were collected and analyzed by Western blotting using the
indicated antibodies. (G) Treatment with chemotherapeutic agents
does not engage necrosis in vivo. On and off Dox lymphoma-
bearing mice were left untreated or treated with a single 200-mL
dose of CTX (30 mg/mL). After 7 d, lymph nodes were harvested,
prepared for single-cell suspension, sorted for CD43 B cells, and
analyzed by Western blotting using the indicated antibodies.
Chien et al.
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NF-kB contributes to chemotherapeutic
drug-induced senescence
To examine the effect of NF-kB inhibition on drug-induced
senescence in vivo, we transplanted the pre-B-cell cultures
described above into nontransgenic, sublethally irradiated
recipient mice (BL6/Ly5.1). Lymphoma-bearing mice were
left untreated or treated with Dox to induce shRNAs
targeting p65. Two weeks later, mice were then injected
with a single dose of CTX to induce a senescence response,
and monitored for NF-kB activation as well as the impact
of NF-kB suppression on senescence.
Consistent with our results in human fibroblasts, p65
phosphorylation was induced by chemotherapy in vivo
(Fig. 5A). Furthermore, lymphomas from mice on Dox
(harboring lymphomas with suppressed p65 expression)
showed less accumulation of p15INK4b protein (Fig. 5A)
and no apparent SA-b-gal staining (Fig. 5B) 7 d after CTX
treatment, with no obvious differences in the amount of
apoptosis and necrosis detected (data not shown). Of note,
suppression of p65 had no impact on cell proliferation of
Arf/ Em-myc lymphomas treated with chemotherapy in
vitro, a setting where drug treatment produces an apo-
ptotic response rather than senescence (Supplemental
Fig. 3; Schmitt et al. 1999). Thus, in a setting where
apoptosis is suppressed, silencing NF-kB expression im-
pairs the senescence response to chemotherapy in vivo.
We isolated lymphomas from mice to examine global
gene expression using Affymetrix Mouse Gene 1.0 ST
arrays. We found NF-kB was consistently activated 7 d
after CTX treatment, as evidenced by increased transcrip-
tion of a series of NF-kB target genes (target list from
http://bioinfo.lifl.fr/NF-KB) (P < 0.05) (Fig. 5C), some of
which were confirmed by RT-qPCR (data not shown).
Moreover, GO analysis indicated that at this late time
point themost significantly down-regulated genes in CTX-
treated lymphomas were linked to the cell cycle (P = 1.103
109) and DNA replication (P = 4.58 3 1012) (Fig. 5D,E),
while the most significantly up-regulated genes were
related to the immune response (P = 0.02) and included
key SASP components (Fig. 5F). Interestingly, CTX-treated
lymphomas with attenuated p65 expression showed in-
creased expression of cell cycle (P = 1.533 108) and DNA
replication (P = 8.14 3 1010) (Fig. 5D,E) genes, but
suppressed expression of immune response-related genes
(P = 0.02) (Fig. 5F). In addition, these lymphomas incorpo-
rated more BrdU (Fig. 5G) and showed less infiltration of
immune cells, especially NK cells (Fig. 5H), following
chemotherapy. Together, these results are consistent with
those observed in IMR-90 cells, where NF-kB influenced
both cell-autonomous and non-cell-autonomous compo-
nents of the senescence program.
Disruption of NF-kB leads to chemoresistance
and reduced survival
To address the significance of NF-kB suppression on treat-
ment outcome in murine lymphomas expressing c-Myc
and Bcl-2, wemonitored lymphoma progression in diseased
animals following chemotherapy. Lymphoma-bearingmice
were left off Dox or put on Dox to induce GFP fluorescence
Figure 5. NF-kB inhibition compromises drug-induced senes-
cence. (A) Activation of NF-kB occurs in chemotherapy-induced
senescent lymphomas. Lymphoma-bearing mice with or with-
out Dox treatment were injected with a single 200-mL dose of
CTX (30 mg/mL) (n = 2 for each condition, except the CTX-
untreated control). Lymph nodes from these mice were har-
vested and sorted for CD43 B cells, and whole-cell lysates were
prepared and analyzed by Western blotting using the indicated
antibodies. (B) Loss of p65 function bypasses drug-induced
senescence. Seven days after CTX injection, lymph nodes from
off Dox (p65-expressing) and on Dox (p65 knockdown) mice
were harvested, cryo-sectioned, analyzed for SA-b-gal activity,
and counterstained with eosin. (C–F) Heat map of differentially
expressed NF-kB targets (C), cell cycle (D), DNA replication (E),
and cytokine–cytokine receptor interaction genes (F) in each
indicated condition (refer to Supplemental Table 3 for the full
list of genes). (G) Inhibiting p65 function promotes cell growth
after CTX treatment. Seven days after CTX injection, off Dox
(p65-expressing) and on Dox (p65 knockdown) mice were
injected intraperitoneally (i.p.) with 200 mL of BrdU solution
(10 mg/mL) and sacrificed 2 h later. Lymph nodes from these
mice were harvested, cryo-sectioned, immunostained for BrdU
(red), and counterstained with DAPI (blue). Values represent
means + SEM of at least three independent animals; (*) P < 0.05
using Student’s t-test. (H) Loss of p65 function abrogates NK cell
infiltration. Seven days after CTX injection, lymph nodes from
off Dox (p65-expressing) and on Dox (p65 knockdown) mice
were harvested, and single-cell suspensions were prepared and
analyzed for the presence of specific immune cell types by flow
cytometry. Percentages of total CD45.2+ cells are indicated.
Values represent means + SEM of at least three independent
animals; (*) P < 0.05 using Student’s t-test.
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and p65 shRNA expression. Notably, no difference in the
progression of established lymphomaswas observedwhen
NF-kB activity was inhibited by the p65 shRNA as as-
sessed by peripheral lymph node enlargement and spleen
size (data not shown).Micewere then treatedwith a single
injection of CTX and monitored for disease regression,
relapse, and survival.
When p65 levels were unaltered (off Dox), lymphomas
responded rapidly toCTXby regressing to a nondetectable
stage after 3 wk. In contrast, mice expressing the p65
shRNA (on Dox) displayed virtually no response to CTX
as assessed by lymph node palpation (Fig. 6A). This result
was not due to unanticipated effects of Dox treatment,
since mice harboring an independent lymphoma contain-
ing shRNA against Renilla luciferase responded normally
to chemotherapy in the presence of Dox (Supplemental
Fig. 4). Consistent with the nonresponsiveness of lym-
phomas expressing p65 shRNAs to chemotherapy, mice
harboring these lymphomas showed a dramatically re-
duced survival compared with controls (Fig. 6B).
Whole-body fluorescence imaging of mice after 3 wk of
CTX treatment indicated that shp65-expressing lympho-
mas (which are GFP positive) had overrun the lymph
nodes, bones, and other organs of recipient mice that
matched the anatomical locations of lymphoma pathology
(Fig. 6C). In addition, the spleens from mice with sup-
pressed NF-kB expression were significantly larger than
controls post-chemotherapy (Fig. 6D). Histopathological
analysis of spleens and livers showed highly disseminated
lymphomas in the Dox-treated (p65-suppressed) animals,
with infiltration to the livers after chemotherapy, whereas
at this time point little infiltration was detected in the
livers of ‘‘off Dox’’ mice (Fig. 6E). Thus, in this in vivo
context, NF-kB inhibition promotes drug resistance.
Importantly, NF-kB inactivation also bypassed senescence
and promoted tumor progression in a murine hepatocellu-
lar carcinoma model in which p53 reactivation induces
senescence (Supplemental Fig. 5; Xue et al. 2007), suggest-
ing that the role of NF-kB in controlling senescence
phenotypes is not unique to fibroblasts and lymphoma.
Discussion
The senescence program involves a complex interplay
between cell-intrinsic and cell-extrinsic processes that
influence the senescence-associated cell cycle arrest, the
tissuemicroenvironment, and the surveillance of senescent
cells by various immune system components (Kuilman
and Peeper 2009). Emerging evidence indicates that the
SASP can reinforce the senescence arrest and mediate
cross-talk between senescent cells and other cells within
their microenvironment (Krtolica et al. 2001; Acosta
et al. 2008; Krizhanovsky et al. 2008; Kuilman et al.
2008). By implicating NF-kB as a major transcriptional
modulator in senescence that is required for SASP, our
study further supports the importance of the SASP for
the senescence program both in vitro and in vivo. Indeed,
by disrupting a key mediator of this program, we show
that the SASP is important for both the cell-autonomous
and non-cell-autonomous components of senescence,
stabilizing cell cycle arrest and promoting immune cell
clearance. Consequently, our study has ramifications for
understanding the mechanisms of senescence as they
pertain to tumor suppression, and the action of NF-kB in
cancer biology and as a therapeutic target.
Recent studies suggest that NF-kB can influence DNA
damage responses and genomic instability during senes-
Figure 6. NF-kB inhibition leads to chemoresistance and poor
survival in murine lymphomas. (A) Loss of p65 function results
in chemoresistant lymphomas. Kaplan-Meier analysis of tumor-
free survival as measured by lymphoma palpability following
CTX therapy. Day 0 equals the day of CTX treatment. Curves
reflect the responsiveness of off Dox (p65-expressing) (black line,
n = 15) and on Dox (p65 knockdown) (red line, n = 15)
lymphoma-bearing mice to CTX therapy. (B) Loss of p65
function leads to poor prognosis following chemotherapy.
Kaplan-Meier survival analysis of on/off Dox lymphoma-bearing
mice following CTX therapy (n = 10 for each group). Day
0 equals the day of CTX treatment. (C) Lymphoma-bearing mice
with or without Dox treatment were sacrificed 3 wk after CTX
injection and imaged for GFP. While lymphomas in off Dox mice
(p65-expressing) regressed to undetectable levels, lymphomas in
on Dox mice (p65 knockdown) persisted. (D) Suppression of p65
function leads to chemoresistant lymphoblastic neoplasms.
Hematoxylin and eosin staining of spleens and livers from the
on/off Dox diseased animals after CTX injection. Mice on Dox
(p65 knockdown) showed a much more aggressive lymphoblas-
tic disease. (E) Spleens from the on/off Dox diseased animals
after CTX injection were dissected and weighed. Values repre-
sent means + SEM from at least four independent animals per
group; (*) P < 0.05 using Student’s t-test.
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cence and implicated the DNA damage response as a
trigger for SASP (Rodier et al. 2009;Wang et al. 2009). How-
ever, in our system, p65 attenuation did not significantly
alter the expression of DNA damage response genes or the
accumulation of DNA damage foci following the intro-
duction of oncogenic Ras (Supplemental Fig. 6); hence, NF-
kB does not mediate the DNA damage response associated
with oncogene-induced senescence. Instead, our data sug-
gest that NF-kB directly controls the SASP by influencing
the expression of NF-kB target genes.
The NF-kB pathway is critically involved in many
aspects of the immune system, from the development of
immune cells and organs to the proper functioning of
innate and adaptive immunity (Hayden et al. 2006;
Hoffmann and Baltimore 2006). However, its role in cancer
biology is less well defined and sometimes paradoxical.
Beyond its role in mediating inflammatory responses
that can influence cancer progression via the microen-
vironment (Karin 2006), most studies suggest that the
cell-intrinsic activities of NF-kB play a pro-oncogenic
role during cancer progression, perhaps through regu-
lating survival genes in cancers. Indeed, recent work
documents an essential role for NF-kB signaling in
promoting progression of murine lung adenocarcinomas
harboring activated K-ras and p53mutants (Meylan et al.
2009).
Despite these well-established links, some studies sug-
gest that NF-kB can promote rather than suppress apopto-
sis, suggesting it might have tumor-suppressive activity
(Ryan et al. 2000). Consistent with this, we detect a
marked increase in NF-kB phosphorylation, nuclear
translocation, and chromatin association during onco-
gene-induced senescence, and show that NF-kB controls
a major transcriptional module that, in this context, is
independent of the other major tumor suppressors: RB
and p53. Although one report suggests that enforced
NF-kB activity can bypass oncogene-induced senescence
(Rovillain et al. 2011), we clearly see, using loss-of-
function studies, that NF-kB actively contributes to the
senescence process in vitro and in vivo. Consistent with
our results, NF-kB is also activated and contributes to cell
cycle arrest in immortalized epithelial cells following
withdrawal of SV40 Tantigen (Hardy et al. 2005; Rovillain
et al. 2011). Moreover, superrepressor IkB cooperates with
Ras in transforming skin epithelial cells, in part by
preventing down-regulation of CDK4 (Dajee et al. 2003).
By identifying NF-kB as a master regulator of the SASP, we
could use NF-kB inhibition to explore the impact of this
‘‘subroutine’’ on the biological output of the senescence
program. In our in vivo lymphoma model, the apoptotic
program is suppressed by Bcl-2 overexpression, such that
the senescence response becomes the decisive factor for
chemosensitivity and treatment outcome. Under such
conditions, we see that disruption of SASP through NF-
kB inhibition promotes chemoresistance of lymphomas
mainly through a failure to engage the senescence re-
sponse that contributes to cell cycle arrest and triggers
immune clearance of the senescent cells. Consequently,
animals harboring lymphomas with suppressed NF-kB
show early relapse and poor survival post-therapy.
Although our in vivo work was intended to explore
senescence biology in a tractable setting and not precisely
recapitulate a particular disease entity, our model approx-
imates the situation observed in patients with progressed
follicular lymphoma, aggressive ‘‘double-hit’’ B-cell lym-
phomas with MYC and BCL2 translocations, and the
germinal center B-cell-like (GCB) type of diffuse large B-cell
lymphomas (DLBCLs) (Nogai et al. 2011). In all of these
settings, Bcl-2 translocations enforce a strong apoptotic
block, and recent transcriptome analyses of GCB-DLBCL
indeed suggest that lowNF-kB activity correlateswith poor
treatment outcome in patients harboring lymphomas of
this subtype (Jing et al. 2011). Nonetheless, the situation is
complex, as mutations leading to hyperactivation of NF-kB
occur in the activated B-cell-like (ABC) subtype of DLBCLs,
where the pro-oncogenic functions of NF-kB likely pre-
dominate (Compagno et al. 2009; Davis et al. 2010).
Regardless, our studies support the notion that, in some
contexts, NF-kB can have a tumor-suppressive function
and imply that a component of this effect occurs through
a non-cell-intrinsic mechanism.
Although the precise mechanism underlying the pro-
and anti-oncogenic activities of NF-kB remains to be
determined, it is interesting that several factors important
for the induction of senescence have oncogenic activities
in other contexts. For example, many triggers of senes-
cence can be pro-oncogenic, including Ras and Raf. Medi-
ators also can have an oncogenic role, such as HMGA2,
MEK, and certain chromatin-modifying enzymes (Lin et al.
1998; Zhu et al. 1998; Ohtani et al. 2001; Narita et al.
2006). Perhaps these factors transmit both pro- and anti-
oncogenic signals as part of various coordinated cellular
programs—for example, to promote wound healing re-
sponses (Krizhanovsky et al. 2008)—and only when the
senescence machinery is disabled do they unleash their
full oncogenic potential. Consistent with this notion, both
MAPK signaling and the reprogramming factor KLF4 can
trigger senescence or transformation, depending on the
status of components of the senescencemachinery (Woods
et al. 1997; Lin et al. 1998; Zhu et al. 1998; Ohtani et al.
2001; Rowland et al. 2005). Moreover, the murine lung
carcinomas that respond to NF-kB inhibition have
bypassed senescence through mutant p53 (Meylan et al.
2009; Feldser et al. 2010). Navigating these context-de-
pendent activities will be important for effectively using
NF-kB inhibitors in the clinic.
Materials and methods
Cell culture and gene transfer
Human diploid IMR-90 fibroblasts (American Type Culture
Collection) were cultured in Dulbecco’s modified Eagle’s medium
(DMEM) supplemented with 10% fetal bovine serum (FBS) and
penicillin and streptomycin (GIBCO). Retroviruses were packaged
using Phoenix cells (G. Nolan, Stanford University, CA), and
infections were performed as described (Narita et al. 2003). The
infected population was selected using 2 mg/mL puromycin
(Sigma) for 2 d, 100 mg/mL hygromycin B (Roche) for 3 d, or 500
mg/mL neomycin for 10 d. For coinfection, IMR-90 cells were
sequentially selected with puromycin, then hygromycin.
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Senescence assays
Senescence was induced by etoposide (100 mM; Sigma) treat-
ment or infection of IMR-90 cells with oncogenic H-RasV12 as
described (Narita et al. 2003). Senescent IMR-90 cells (post-
selection day 8) were plated on coverslips coated with 0.1%
gelatin and fixed in 4% formaldehyde. For cell cycle arrest
analyses, cells were labeled with BrdU (100 mg/mL; Sigma) and
5-fluor-29-deoxyuridine (10 mg/mL; Sigma) for 6 h. Nuclei
incorporating BrdU were visualized by immunolabeling with
anti-BrdU antibodies (1:400; BD Pharmingen) as described pre-
viously (Narita et al. 2003). For colony formation assays, 1250,
2500, or 5000 cells were plated in each well of a six-well plate.
Cells were cultured for 14 d, then fixed with 4% formaldehyde
and stained with crystal violet. Detection of SA-b-gal activity
was performed as described previously at pH 6.0 for IMR-90
cells and pH 5.5 for mouse tissues. Briefly, 10-mm frozen
sections of tissue or adherent cells were fixed with 0.5%
gluteraldehyde in PBS for 15 min, washed with PBS supple-
mented with 1 mM MgCl2, and stained for 5–6 h in PBS
containing 1 mM MgCl2, 1 mg/mL X-Gal (Roche), and 5 mM
each potassium ferricyanide (Sigma) and potassium ferrocya-
nide (Sigma). Sections were counterstained with eosin (Sigma).
For in vitro cytotoxicity assays, growing or senescent cells were
plated in six-well plates at 50,000 cells per well. YT cells (5 3
105) (from DSMZ) were subsequently added to target cells. The
plates were incubated under normal conditions for 12 h, and
then NK cell cytotoxicity was determined by crystal violet
staining the remaining adherent cells.
Immunoassays
Immunofluorescence staining was performed as previously
described (Narita et al. 2003). NF-kB p65 (C-20, Santa Cruz
Biotechnologies) antibody was used. Alexa Fluor conjugates
(Molecular Probes) were used as the secondary antibodies, and
DNA was visualized with 49-6-diamidino-2-phenylindole (DAPI;
Vector Laboratories). Immunoblotting was carried out as de-
scribed previously (Narita et al. 2003). The following antibodies
were used: NF-kB p65 (C-20, Santa Cruz Biotechnologies),
phospho-NF-kB p65 (Ser 536) (93H1, Cell Signaling), p53 (BD
Pharmingen), p16 (H-156, Santa Cruz Biotechnologies), Ras
(Ab-1, Calbiochem), p21 (C-19, Santa Cruz Biotechnologies),
a-Tubulin (B-5-1-2, Sigma), c-Myc (N-262, Santa Cruz Bio-
technologies), Bcl-2 (N-19, Santa Cruz Biotechnologies), p15
(Cell Signaling), cleaved caspase-3 (Asp 175) (Cell Signaling),
Histone H3 (C-16, Santa Cruz Biotechnologies), HMGB1 (Cell
Signaling), and HMGA1 (Narita et al. 2006). For flow cytom-
etry, cells were collected, resuspended with FACS buffer (5%
FBS in PBS), and stained with the following antibodies:
CD45R/B220, IgM, CD11b (Mac-1), NK1.1, and Ly-6G/Ly-6C
(Gr-1) (BioLegend). Data were collected on an LSRII flow
cytometer (BD Bioscience) and analyzed with FlowJo software
(TreeStar).
Gene expression analysis and RT-qPCR
Total RNAwas isolated using the RNeasy minikit (Qiagen), and
cDNA was obtained using the TaqMan reverse transcription
reagents (Applied Biosystems), used for qPCRs or for cRNA
preparation (Message AmpII [Ambion]), and hybridized to U133
Plus 2.0 microarray (Affymetrix) according to the manufacturer’s
instructions. Data analyses were performed as previously de-
scribed (Chicas et al. 2010). Gene-specific primer sets were
designed using Primer Express 1.5 (sequences available on re-
quest). Real-time PCR was carried out in triplicate using SYBR
Green PCR Master Mix (Applied Biosystems) on the Roche IQ5
ICycler. GAPDH or b-actin served as endogenous normalization
controls. shRNA sequences are available on request.
Generation of transgenic mice with conditional
shRNA expression
We used the vectors and ES cells initially produced by the
Jaenisch laboratory that enable rapid site-specific integration of
regulated transgenes in ES cells. These ES cells (KH2) contain
a frt-hygro-pA ‘‘homing’’ cassette downstream from the ColA1
gene on mouse chromosome 11, as well as a reversible tetracy-
cline transactivator (rtTA;Tet-on) targeted into theRosa26 locus.
In these cells, FLPe recombinase mediates recombination be-
tween the FRTsites located in the ColA1 homing cassette and on
the targeting vector. The correctly integrated clones were
selected by hygromycin. In addition, the presence of an rtTA in
these ES cells allows for rapid screening by Dox administration
to activate GFP and shRNA expression. The ES cells harboring
TRE-shRNA against mouse p65 were produced, and germline
transgenic mice derived from these ES cells were generated using
tetraploid embryo complementation.
Generation of genetically defined lymphomas
Primary pre-B-cell cultures were generated as previously de-
scribed (Whitlock and Witte 1987). Briefly, bone marrow from
4- to 5-wk-old female mice carrying the Rosa-rtTA and the TRE-
shRNA were harvested, infected with a MSCV-Bcl-2-IRES-Myc
retrovirus, and plated in a pre-B-cell culture system containing
RPMI 1640 medium supplemented with 10% FBS, 55 mM
2-mercaptoethanol, 2mMglutamine, penicillin, and streptomycin
(GIBCO). Transduced primary pre-B cells were initially cultured
on irradiated feeder layers supplemented with recombinant
mouse IL-7 (1 ng/mL; R&D). After 1 wk in culture, cells were
expanded in the absence of feeders and IL-7. Cells were immu-
nophenotyped by flow cytometry and determined to be >95%
pre-B cells (i.e., B220+, IgM, and negative for the myeloid/
macrophage-specific marker CD11b/Mac-1). The same proce-
dure was used to generate lymphoma cells containing a TRE-
shRNA against Renilla luciferase.
Monitoring treatment response in vivo
Onemillion cells were transplanted into sublethally irradiated (6
Gy) 4- to 5-wk-old female BL6/Ly5.1 mice. Mice were adminis-
tered ciprofloxacin in the drinking water (125 mg/L; Sigma).
After lymphomas became palpable, mice were either adminis-
tered Dox (Sigma) in water and food or left untreated. After 2 wk
of Dox treatment, mice were injected intraperitoneally (i.p.) with
200 mL of CTX (30 mg/mL; Sigma). Mice were sacrificed at the
time indicated in each experiment after CTX injection. To prepare
single-cell suspensions, spleens or lymph nodes were passed
through a 100-mm cell strainer. To isolate B cells, Mouse Un-
touched B cell Dynabeads (Invitrogen) were used according to the
manufacturer’s instructions. For cell proliferation analysis in vivo,
mice were injected i.p. with 200 mL of BrdU solution (10 mg/mL;
BD Pharmingen) 2 h before sacrifice. Lymphomas were harvested,
cryo-sectioned (10 mm), and stained for BrdU as described pre-
viously. The Cold Spring Harbor Laboratory Animal Care and Use
Committee approved all procedures described in this work.
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